📢 Sydnexis has announced that the FDA has issued a Complete Response Letter for its NDA for SYD-101, a proprietary 0.01% atropine formulation intended to slow myopia progression in children.

Full article: https://ow.ly/W3A850XwTK0

#Ophthalmology #OphthalmologyNews #MyopiaControl

🔎 Catch up on the latest in ophthalmology

From clinical breakthroughs to practice management insights, see what’s shaping the field this week.

👉 Explore the news tab: ow.ly/5WKf50WGzpu

#Ophthalmology #EyeCare #Ophthalmologists #OphthalmologyNews #VisionCare